Dietary squalene increases high density lipoprotein-cholesterol and paraoxonase 1 and decreases oxidative stress in mice by Gabas-Rivera, C. et al.
Dietary Squalene Increases High Density Lipoprotein-
Cholesterol and Paraoxonase 1 and Decreases Oxidative
Stress in Mice
Clara Gaba´s-Rivera1,3, Cristina Barranquero1,3, Roberto Martı´nez-Beamonte1,3, Marı´a A. Navarro1,3,
Joaquı´n C. Surra2,3, Jesu´s Osada1,3*
1Departamento Bioquı´mica y Biologı´a Molecular y Celular, Facultad de Veterinaria, Instituto de Investigacio´n Sanitaria de Arago´n (IIS), Universidad de Zaragoza, Zaragoza,
Spain, 2Departamento de Produccio´n Animal, Escuela Polite´cnica Superior de Huesca, Huesca, Spain, 3CIBER de Fisiopatologı´a de la Obesidad y Nutricio´n, Instituto de
Salud Carlos III, Madrid, Spain
Abstract
Background and Purpose: Squalene, the main hydrocarbon in the unsaponifiable fraction of virgin olive oil, is involved in
cholesterol synthesis and it has been reported to own antiatherosclerotic and antiesteatosic effects. However, the
squalene’s role on lipid plasma parameters and the influence of genotype on this effect need to be addressed.
Experimental Approaches: Three male mouse models (wild-type, Apoa1- and Apoe- deficient) were fed chow semisynthetic
diets enriched in squalene to provide a dose of 1 g/kg during 11 weeks. After this period, their plasma parameters and
lipoprotein profiles were analyzed.
Key Results: Squalene administration at a dose of 1 g/kg showed decreased reactive oxygen species in lipoprotein fractions
independently of the animal background and caused an specific increase in high density lipoprotein (HDL)-cholesterol
levels, accompanied by an increase in phosphatidylcholine and paraoxonase 1 and no changes in apolipoproteins A1 and
A4 in wild-type mice. In these mice, the cholesterol increase was due to its esterified form and associated with an increased
hepatic expression of Lcat. These effects were not observed in absence of apolipoprotein A1. The increases in HDL-
paraoxonase 1 were translated into decreased plasma malondialdehyde levels depending on the presence of
Apolipoprotein A1.
Conclusions and Implications: Dietary squalene promotes changes in HDL- cholesterol and paraoxonase 1 and decreases
reactive oxygen species in lipoproteins and plasma malondialdehyde levels, providing new benefits of its intake that might
contribute to explain the properties of virgin olive oil, although the phenotype related to apolipoproteins A1 and E may be
particularly relevant.
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Introduction
Virgin olive oil is the main source of fat in the Mediterranean
dietary pattern, and it was shown an important relationship
between olive oil intake and the reduced cardiovascular risk [1],
[2], [3], and even cardiovascular mortality [4]. The mechanism of
this protective effect of virgin olive oil intake still needs to be
elucidated. It was firstly attributed to its main components,
monounsaturated fatty acids, and especially to the most abundant,
oleic acid. However, the interest has been lately focused on its
minor bioactive components since biological actions of these
compounds have been documented [2,5–7].
Squalene, first isolated from shark liver oil and named by
Tsujimoto in 1916 [8], is a polyunsaturated triterpene containing
six isoprene units and a biochemical precursor of cholesterol and
other steroids [9]. Squalene content in extra virgin olive oil is
especially high, up to 0.7% (7 g/kg), compared to other oils and
human dietary fats [10], [11]. In vitro, it is a highly effective
oxygen scavenging agent [12] and stable in virgin olive oil heated
at 180uC for 36 h [13]. For these reasons, it has been even stated
that squalene rather than oleic acid could be the important active
compound of virgin olive oil [14].
In humans, orally administered squalene is well absorbed (60–
85%). This and the intestinal de novo synthesized squalene are
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transported by chylomicrons into circulation, being rapidly taken
up by the liver, where it is converted into sterols and bile acids [15]
or secreted into bloodstream [16,17]. Hepatic squalene, either
biosynthesized or dietary, is secreted into very low density
lipoproteins (VLDL) and low density lipoproteins (LDL) and
distributed to various tissues. Skin is also a biosynthetic tissue for
squalene to provide the large quantities found in the sebaceous
glands [18], [19]. Therefore, squalene concentration in plasma
lipoproteins represents an equilibrium from dietary intake, with
important amounts coming from extra virgin olive oil, and
intestinal or liver synthesis [20].
Nonetheless, it is not clear yet squalene’s role on plasma lipids in
humans and animal models. While some authors did observe
increased plasma cholesterol after squalene intake in rats [21] and
in hamsters [22], others did not in humans [23], neither in rats
[24] nor in Apoe-deficient mice [25]. These discrepancies raise the
questions of whether animal models or administration regimens
(length and doses) are modifying squalene’s effect on plasma
cholesterol. Another aspect requiring attention is the long-term
effects and safety of high dose of squalene consumption [26].
Mice are considered high density lipoprotein (HDL) animals,
since they lack cholesteryl ester transfer protein and most of their
plasma cholesterol is transported in these lipoproteins [27].
Among mouse strains, C57BL/6J genetic background is widely
used due its higher predisposition to atherosclerosis development
[28]. Moreover, mice have been subjects of intensive genetic
manipulation, and genes codifying for proteins associated with
HDL have been created and tested to study their biological
functions [29]. Indeed, mice lacking apolipoprotein A1 (APOA1),
the main component of HDL, offer the possibility to explore
changes in absence of HDL-containing APOA1 [30]. Apoe-
deficient mice lack HDL-containing APOE, hence no apolipo-
protein E can be transferred to remnant chylomicrons, and the
latter are not taken up by the liver [31]. Both Apoa1- and Apoe-
deficient mice are also available on C57BL/6J genetic back-
ground. Therefore, these models provide interesting experimental
approaches to analyze the specific influence of these genotypes on
the observed outcome following the long term administration of a
semipurified diet supplemented with squalene. To this end, plasma
parameters and lipoprotein profiles, gene expression and oxidative
parameters will be analyzed in these three mouse models.
Results
Body and liver weight
Animal somatometric variables are shown in Table 1. In the
studied models, the administration of dietary squalene had no
effect on body weight, body weight gain or feed intake (data not
shown). Besides, no significant changes were observed for liver
weight, with the exception of a slight significant increase of this
parameter in WT mice consuming the diet enriched in squalene
that was not translated into changes of hepatic fat content
measured as lipid droplet extent (data not shown). These results
suggest that long term squalene administration is well tolerated in
terms of body weight changes.
Plasma parameters
The effects of squalene on plasma parameters in WT, Apoa1-
and Apoe-deficient mice after the 11-week experimental period are
shown in Tables 2, 3 and 4. There were no significant differences
in plasma triglycerides, neither in total cholesterol when the 1 g/
kg squalene dose was provided to any mouse model. Nevertheless,
a dose of 0.25 g/kg squalene significantly increased total
cholesterol levels in Apoe-deficient mice (Table 4). HDL-choles-
terol levels were raised in all mouse models when they were
administered the high squalene dose. The increased HDL-
cholesterol in wild type was not accompanied by increases in
APOA1, nor in APOA4. However, paraoxonase, estimated as
arylesterase activity, was increased in WT and Apoa1-deficient
mice (Tables 2 and 3). Wild-type and Apoa1-deficient mice
consuming 1 g/kg squalene (Tables 2 and 3) also showed
increased plasma glucose levels. Non-esterified fatty acids were
increased in wild-type and Apoe-deficient mice consuming 1 g/kg
and 0.25 g/kg of squalene, respectively.
Effect of squalene on lipoprotein profiles
The distribution of the plasma parameters in lipoprotein
fractions separated by FPLC from the different mouse models is
shown in Figure 1. According to the model, cholesterol distribu-
tion changed. In this regard, cholesterol was mainly carried in
HDL in WT mice (Fig. 1A), lower cholesterol levels in the latter
lipoproteins and some cholesterol in VLDL and LDL fractions
were observed in Apoa1-deficient mice (Fig. 1G), and the plasma
cholesterol of Apoe-deficient mice was mainly accumulated in
VLDL fraction (Fig. 1L). In wild-type mice, squalene administra-
tion induced an increase in HDL cholesterol (Fig. 1A), mainly due
to esterified cholesterol (Fig. 1B), that was accompanied by
increased HDL phosphatidylcholine (Fig. 1C), whilst no changes
in sphingomyelin and APOA1, and redistribution of APOA4
towards smaller HDL particles were observed. In Apoa1-deficient
mice, squalene did not have any effect on cholesterol distribution
(Fig. 1G and H), decreased phosphatidylcholine (Fig. 1I) and
increased APOA4 in HDL particles (Fig. 1K) and did not modify
HDL sphingomyelin but decreased this phospholipid in LDL
(Fig. 1J). In Apoe-deficient mice, squalene administration at either
studied dose had little effect on cholesterol, esterified cholesterol,
phosphatidylcholine and sphingomyelin (Fig. 1, panels L, M, N
and O, respectively). However, it increased the presence of
APOA4 in HDL and decreased LDL APOA4 (Fig. 1Q). Thus,
these results indicate that squalene is modifying HDL composition
depending on the presence of APOE and APOA1.
Oxidative stress variables
As shown in Figures 2A and 2B, isolated LDL from the
squalene-treated groups had significantly lower levels of reactive
oxygen species than LDL from control animals in WT as well as in
Apoa1-deficient mice. This effect was not observed in Apoe-
deficient mice (Fig. 2C), although in this model receiving the high
squalene dose, the ROS content in VLDL was significantly
decreased as in wild-type. According to the modified HDL
composition, a decrease in HDL-ROS levels was found in the
three genotypes of mouse by the squalene administration, but
there were no differences in the ability of HDL to inactivate LDL
ROS species (Fig. 2A and B), except for Apoe-deficient mice, as
LDL particles from WT and Apoa1-deficient squalene-receiving
mice present already very low levels of ROS compared to control
mice.
Figure 2 (panels D and F) shows significant decreases of plasma
malondialdehyde (MDA) levels in WT and Apoe-deficient mice
receiving squalene at 1 g/kg dose, what is an indicator of lower
oxidative levels induced by squalene intake. No significant changes
were seen in Apoa1-deficient mice (Fig. 2E). To corroborate
whether the results of arylesterase activity corresponded to PON1,
its HDL levels were determined. As shown in Figure 2 (panels G
and I), mice administered squalene at 1 g/kg showed increased
HDL-PON1 in WT and Apoe-deficient mice. No significant
changes were observed in Apoa1-deficient mice (Fig. 2H). Since
PON2 is a ubiquitous antioxidant enzyme [32], we investigated
Squalene and Plasma Lipoproteins
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whether the squalene administration induced any differential
hepatic mRNA expression in wild-type mice. According to results
depicted in Table 5, hepatic Pon2 expression was increased, so
was Pon1. Furthermore, the hepatic mRNA expression of
prenylcysteine oxydase 1, Pcyox1 (a pro-oxidant enzyme of LDL
[33]) was also tested (Table 5), and no significant change was
observed either. Hepatic Pcyox1 expression was found significantly
associated with Pon2 expression and with plasma cholesterol
(Figure 3A and B). In contrast, hepatic Lcat expression was
significantly increased (Table 5) and significantly associated with
that of Pon1 (Figure 3C).
Discussion
The aims of present study were to verify the influence of genetic
background and long-term administration of squalene on mouse
plasma parameters and lipoprotein distribution in different mouse
models. After 11-week administration, the main findings were that
a high dose of squalene (1 g/kg mouse) increased HDL-cholesterol
and PON1 levels with independence of the genetic background
without increasing total cholesterol and thus decreasing total/
HDL-cholesterol ratio. The increase in HDL-cholesterol was
mainly due to increased esterified cholesterol and phosphatidyl-
choline, in absence of changes in APOA1 and APOA4 levels and
correlated with arylesterase activity, PON1 levels and hepatic Lcat
mRNA expression in wild-type mice. Furthermore, lipoprotein
ROS content was diminished by squalene administration in
function of genotype. Overall, squalene is an important modifier of
HDL metabolism with important differences regarding genotype
and dose.
The highest squalene dose used in the present study was 1 g/
kg/day, which is five times lower than the lethal dose 50 (5 g/kg/
day) [34] and far lower than the dose required to induce
encephaloneuropathy in rats (20 g/kg/day) [35]. Considering
the higher metabolic rate of mice [36], our dose would translate
into a human of 100 mg/kg/day. This is clearly higher than the
highest reported in human nutritional studies (15 mg/kg/day)
[17], but lower than the pharmacological doses of 185 and
385 mg/kg/day provided to female volunteers for 90 days [37].
Therefore, the present study uses a dose higher than those
provided in human nutritional interventions, but lower than the
used in pharmacological trials.
HDL levels are an inverse risk factor for coronary artery
diseases and the total/HDL-cholesterol ratio has been reported to
be a better predictor of ischemic heart disease than other
conventional risk markers (total cholesterol, LDL-cholesterol or
triacylglycerides) [38–42]. In this way, a high dose of 1 g/kg of
squalene could be protective since it raised HDL-cholesterol
Table 1. Effect of the experimental diets on somatic variables in male mice of the three experimental models.
Final body weight (g) Body weight gain (g) Liver weight (g)
Wild-type
Control (n = 6) 3061 3.161.2 1.260.1
Squalene (1 g/kg) (n = 7) 3062 3.662.2 1.360.1*
Apoa1-deficient
Control (n = 7) 2964 4.865.0 1.060.3
Squalene (1 g/kg) (n = 7) 2763 2.865.1 1.060.2
Apoe-deficient
Control (n = 13) 3562 5.562.2 1.860.9
Squalene (0.25 g/kg) (n = 13) 3463 4.762.4 1.660.3
Squalene (1 g/kg) (n = 14) 3363 4.561.8 1.660.4
Results are shown as mean values with their standard deviations. Statistical analysis was carried out using Mann Whitney U test.
* p,0.05 vs control.
doi:10.1371/journal.pone.0104224.t001
Table 2. Effect of dietary squalene supplementation on plasma parameters in male wild-type mice.
Control (n = 6) Squalene 1 g/kg (n = 7)
Total cholesterol (mM) 5.960.7 6.560.8
HDL-cholesterol (mM) 2.660.5 3.160.4*
Triglycerides (mM) 1.860.5 1.660.4
Glucose (mM) 1861 2061*
Non-esterified fatty acids (mM) 0.860.1 1.060.2*
APOA1 (AU) 2062 1961
APOA4 (AU) 761 761
Arylesterase activity (6103 IU/L) 6366 6963*
Results are shown as mean values with their standard deviations. Statistical analysis was carried out using Mann Whitney U test.
* p,0.05 vs control.
AU, arbitrary units.
doi:10.1371/journal.pone.0104224.t002
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without modifying total cholesterol in all studied mouse models,
confirming our previous study using this dose [25]. However, an
increase in total cholesterol was observed at a low squalene dose
(0.25 g/kg mouse) in Apoe-deficient mice without increasing
HDL-cholesterol. In this regard, discrepant effects of squalene
on plasma lipids have been previously reported. Indeed, a lowering
plasma cholesterol effect was described in rats using a 1 g/kg dose
during 4 weeks [24] and the opposite was also found in this animal
consuming the same dose in corn oil [21]. In humans, dietary
supplementation of squalene at 12 mg/kg formulated in rapeseed
oil for nine weeks was reported to cause increases in total and
LDL-cholesterol concentrations [16] or not to have effect when
provided as pills [23]. However, a subsequent six-week period on a
lower dose of 6 mg/kg normalized serum sterols [43]. Low dose
had a hypercholesterolemic effect in hamsters [22] as well. This
discrepant outcome shows that squalene effect on plasma
cholesterol is dose dependent, as low doses seem to promote
cholesterol synthesis (squalene is an intermediary in cholesterol
biosynthesis), and high doses might have a different effect. A
potential action could be related to an intestinal contribution as
well. In fact, the high doses of 185 and 385 mg/kg/day provided
to female humans for 90 days [37] elicited presence of steatorrhea,
whose percentage of incidence was dose-dependent. Overall, doses
and matrices of squalene administration may have a profound
influence.
Another interesting aspect noted in WT mice receiving squalene
was that the increase in HDL-cholesterol was mainly due to
augmented esterified cholesterol (Fig. 1B). This fact indicates that
the activity of the enzyme responsible for this type of cholesterol in
HDL, lecithin:cholesterol acyltransferase (LCAT), was increased.
Elevated hepatic Lcat mRNA expression (Table 5) supported this
finding. LCAT plays an important physiological role in the process
of maturing HDLs, modulating the conversion of HDL3 to HDL2,
and thereby collecting cholesterol from peripheral tissues and
increasing HDL levels [44]. In these WT mice, HDL was enriched
in phosphatidylcholine (PC) (Fig. 1C), which is the substrate for
the LCAT activity [45], indicating that squalene is favoring the
secretion of an HDL enriched in LCAT and with an appropriate
endowment of PC to facilitate its action and thereby reverse
cholesterol transport and without changes in the LCAT activators
APOA1 or APOA4 [46]. Since secretion of LCAT is associated
with APOA1 [47], these changes would not be possible in its
absence, as in the case of Apoa1-deficient mice. In Apoe-deficient
mice, it would not be possible either, due to the high content of
remnant and intermediate density lipoproteins characteristics of
this model [31]. For this reason, in these mice important amounts
of APOA1 and APOA4 were observed in VLDL and LDL
(Fig. 1P and Q), suggesting incomplete liberation of nascent HDL
from chylomicrons/VLDL according to the hypothesis of HDL
secretion as part of those lipoparticles [48] and in agreement with
the postprandial time follow-up of APOA4 distribution [49]. In
this setting, squalene would promote a maturation of HDL by
transferring these APOS to the HDL fraction. Overall, squalene is
exerting important effects on these lipoproteins depending on their
inherent metabolic characteristics present in the studied model.
The increase in HDL-cholesterol levels found in this study was
also accompanied by a significant increase in serum arylesterase
activity in WT and Apoa1-deficient mice consuming squalene, in
Table 3. Effect of dietary squalene supplementation on plasma parameters in male Apoa1-deficient mice.
Control (n = 7) Squalene 1 g/kg (n = 7)
Total cholesterol (mM) 0.860.4 0.960.3
HDL-cholesterol (mM) 0.460.1 0.660.1*
Triglycerides (mM) 0.660.2 0.560.1
Glucose (mM) 2062.0 2260.6*
Non-esterified fatty acids (mM) 0.560.1 0.560.1
Arylesterase activity (6103 IU/L) 4863 5162*
Results are shown as mean values with their standard deviations. Statistical analysis was carried out using Mann Whitney U test.
* p,0.05 vs control.
doi:10.1371/journal.pone.0104224.t003
Table 4. Effect of dietary squalene supplementation on plasma parameters in male Apoe-deficient mice.
Control (n = 13) Squalene 0.25 g/kg (n = 13) Squalene 1 g/kg (n = 14)
Total cholesterol (mM) 2366 2862** 2168‘‘
HDL-cholesterol (mM) 0.960.2 0.860.3 1.160.2*‘
Triglycerides (mM) 3.461.3 3.760.9 3.461.4
Glucose (mM) 2263 2463 2163‘
Non-esterified fatty acids (mM) 1.560.3 1.760.3** 1.460.6
Arylesterase activity (6103 IU/L) 7766 7865 7864
Results are shown as mean values with their standard deviations. Statistical analysis was carried out using Mann Whitney U test.
*p,0.05,
**p,0.01 mean values were significantly different from those of the control diet, and
‘p,0.05,
‘‘p,0.01 mean values were significantly different between 0.25 and 1 g/kg squalene doses.
doi:10.1371/journal.pone.0104224.t004
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HDL-PON1 and Pon1 mRNA expression in WT mice and in
HDL-PON1 in Apoe-deficient mice consuming 1 g/kg of squa-
lene. Human PON1 is synthesized in the liver and secreted into
the blood, where it is mainly associated with HDLs [50],
hydrolyzes oxidized phospholipids and protects against the
development of atherosclerosis [51,52]. HDL’s ability to prevent
oxidative modifications of LDL has been attributed to PON1
[53,54]. The observed rise in this enzyme activity could likely
explain the decreased ROS content in VLDL, LDL and HDL
together with PON2 due to the changes observed for Pon2 and
Pon1 in WT mice. In the case of Apoa1-deficient mice, no changes
were found either in HDL-PON1 or in hepatic Pon1 expression,
but Pon2 and Pcyox1 mRNA were significantly decreased (data
not shown), so increased serum arylesterase activity and decreased
Pcyox1 in liver could explain the decrease in LDL- and HDL-
ROS content of mice lacking Apoa1 consuming squalene. In the
latter mice, HDL-PON1 was not changed and together with
absence of APOA1, the changes induced by squalene on HDL
were inefficient to decrease MDA levels (Fig. 2E). On the other
hand, when HDL-PON1 increased by squalene such as in WT
and in Apoe-deficient mice receiving 1 g/kg, there were significant
decreases in MDA levels. Overall, these results indicate that
squalene is exerting an antioxidant action mediated by inducing
PON1 content of HDL and that this action requires the presence
of APOA1. In this regard, squalene behaves like compounds from
pomegranate juice, which decreased oxidative stress in diabetic
patients by increasing PON1 association with HDL and stimulat-
ing its enzyme activity [55,56]. However, as squalene has been
reported to own antioxidant properties as a quencher of singlet
oxygen [57] and as an in vitro highly effective oxygen scavenging
agent [12], a direct involvement of this molecule cannot be
discarded. Furthermore, it has been reported to elicit antioxidant
defense proteins [58]. Thus, the mechanisms whereby squalene
protects against oxidative damage in lipoproteins need to be
further studied.
A well-controlled study was conducted in elderly hypercholes-
terolemic patients using a 12 mg/kg/day dose of squalene for 20
weeks. Despite the fact that this dose alone did not modify plasma
cholesterol levels, when combined with a low dose of pravastatin, it
potentiated the hypolipidemic properties of the statin [59]. These
Figure 1. Effect of squalene on lipoproteins from the three experimental models. Plasma was obtained following 11 weeks of consuming
control or squalene- enriched semipurified diets and after a four-hour fast. Two independent pools of all mice per experimental group were prepared,
except for Apoe-deficient mice, where three plasma pools were utilized. Lipoproteins were separated by FPLC, and collected fractions analyzed for
total cholesterol (A, G, L), esterified cholesterol (B, H, M), phosphatidylcholine (C, I, N), sphingomyelin (D, J, O), APOA1 (E, P) and APOA4 (F, K, Q).
Representative profiles are shown from WT mice, left panels (control and squalene pools consisting of plasma from 6 and 7 mice, respectively),
Apoa1-deficient mice, middle panels (n = 7 for control and n= 7 for squalene plasma pool) and Apoe-deficient mice, right panels (n = 13 for control,
n = 13 for 0.25 g/kg and n=14 for 1 g/kg squalene plasma pool). Fraction numbers 1–6 corresponded to VLDL/chylomicron remnants, 7–13 to low
density lipoproteins, 14–21 to cholesterol-rich HDL and 22–27 to cholesterol-poor HDL (pHDL).
doi:10.1371/journal.pone.0104224.g001
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data together with the described properties found in this work are
promising aspects to go further and clarify some of the emerging
caveats regarding dose, experimental model and administration
matrices.
In conclusion, the increase in plasma HDL-cholesterol and
PON1 levels and the decrease in ROS in VLDL, LDL and HDL
seem to be the mechanisms whereby squalene exerts its beneficial
activity, hence it could be a contributor to the beneficial effects of
Figure 2. Effect of squalene on antioxidative parameters from the three experimental models. ROS levels in lipoprotein fractions from
control and squalene treated mice expressed as arbitrary fluorescence units after incubation of lipoprotein fractions during 24 h with 29,79-
dichlorofluorescein diacetate A) 0.8 mg LDL or VLDL, and 60 ng HDL from WT mice; B) 0.8 mg LDL and 60 ng HDL from Apoa1-deficient mice; C) 1.5 mg
LDL or VLDL, and 60 ng HDL from Apoe-deficient mice. Each pool was assayed in triplicate. Individual plasma malondialdehyde levels from WT (D),
Apoa1-(E) and Apoe-deficient mice (F). HDL-PON1 levels from WT (G), Apoa1-(H) and Apoe-deficient mice (I) with their representative Western blots.
Each pool was assayed in triplicate. Results are shown as means 6 SD. *p,0.05, **p,0.01 according to corrected unpaired t Welch’s test.
doi:10.1371/journal.pone.0104224.g002
Figure 3. Relationship between hepatic gene expression and plasma cholesterol in wild type mice. Direct correlations among Pcyox1
and Pon2 gene expression (A), or plasma cholesterol (B), and Lcat and Pon1 gene expression (C). Association analyses were carried out using
Spearman’s test for non- parametric distributions.
doi:10.1371/journal.pone.0104224.g003
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the virgin olive oil intake on the prevention against cardiovascular
diseases. This squalene action is conditioned by the genetic
background of APOA1 and APOE, characteristics that modulate
the maturation’s state of secreted HDL, the ability to secrete
functional LCAT or the changes in HDL-PON1. In addition,
formulation of dietary squalene in terms of dose and accompa-
nying elements in the alimentary matrix should be carefully
considered to facilitate reproducible results.
Materials and Methods
Animals
Male wild-type (WT) and Apoe-deficient mice on C57BL/6J
genetic backgrounds were obtained from Charles River (Charles
River Laboratories, Barcelona, Spain). Apoa1-deficient mice on
C57BL/6J genetic background were generously provided by Dr.
Nobuyo Maeda from University of North Carolina at Chapel Hill.
To establish groups with similar initial plasma cholesterol, blood
samples were taken from the facial vein after four-hour fasting. All
animals were housed in sterile filter-top cages in rooms maintained
under a 12-h light/12-h dark cycle in the Servicio de Biomedicina y
Biomateriales, University of Zaragoza. All had ad libitum access to
food and water and the study protocol was approved by the Ethics
Committee for Animal Research of the University of Zaragoza.
Diets
All male mice were fed chow semipurified diets and divided into
control group (n = 6 for WT, n = 7 for Apoa1- and n = 13 for Apoe-
deficient mice) and squalene-treated animals (n = 7 for both WT
and Apoa1-deficient mice), these latter receiving 1 g squalene/kg
body weight, except for the Apoe-deficient animals, in which
squalene-treated animals were given two different doses of the
compound: 0.25 (n = 13) or 1 g (n = 14) squalene/kg body weight.
All diets were prepared weekly and stored in an N2 atmosphere at
220uC. Fresh food in excess was provided daily, and the
differences of amount provided and the remaining per cage were
recorded daily, divided into number of animals and used to assess
the average food intake. The animals were fed the experimental
diets for 11 weeks, being well tolerated.
Biochemical determinations
After the experimental period, animals were sacrificed by
suffocation with CO2, blood (0, 7–1 ml per mouse) was collected
via cardiac puncture and centrifuged at 3000 rpm for 5 minutes at
4uC to obtain plasma. Total plasma cholesterol and triglyceride
concentrations were measured in a microtitre assay, using Infinity
commercial kits (Thermo Scientific Madrid, Spain). Plasma HDL-
cholesterol was quantified in the supernatant after precipitation of
apoB particles with phosphotungstic acid–MgCl2 (Roche, Barce-
lona, Spain). Glucose and non-esterified fatty acids were deter-
mined using kits from BioSystems (Barcelona, Spain) and Wako
(Madrid, Spain). Paraoxonase was assayed as arylesterase activity
by the rate of phenylacetate hydrolysis, as described previously
[60]. APOA1 and APOA4 were quantified by ELISA using
specific polyclonal antibodies (Biodesign and Santa Cruz Biotech-
nology), as described previously [61]. Malondialdehyde was
assayed following Conti’s spectrofluorimetric method [62]. Plasma
lipoprotein profile was determined in 100 ml of pooled plasma
samples from each group by fast protein liquid chromatography
(FPLC) gel filtration [63] using a Superose 6B column (GE
Healthcare), and the cholesterol, phosphatidylcholine and sphin-
gomyelin contents in each fraction were measured as described
[49].
Reactive oxygen species (ROS) content in lipoproteins
The presence of ROS was assessed by measuring the conversion
of 2,7-dichlorofluorescein diacetate into fluorescent dichlorofluor-
escein [64] in FPLC-isolated fractions corresponding to the
different lipoproteins [65]. Briefly, LDL or VLDL (0.8 mg
cholesterol for wild-type and Apoa1-deficient mice, and 1.5 mg
cholesterol for Apoe-deficient mice) and HDL (60 ng cholesterol)
were incubated at 37uC with 2 mg dichlorofluorescein in 2.5 ml of
0.1% sodium azide and PBS up to a total volume of 240 ml. After
24 h of incubation, fluorescence was measured at an excitation
wavelength of 485 nm and an emission wavelength of 535 nm
[65]. To study the protective action of HDL against oxidation,
LDL particles were incubated in the presence of its HDL, and
fluorescence was measured.
Western blotting
HDL fractions (30 mg of protein) were loaded onto 12% SDS-
PAGE gels, electrophoresed, and transferred as previously
described [25]. Protein bands were detected using a rabbit
polyclonal anti-PON1 antibody raised against a mouse oligopep-
tide (CYKNHRSSYQTRLNAFREVTP) at dilution 1/1,000 [66].
As secondary antibody, a donkey anti-rabbit conjugated with
IRdye 680RD (926-68073 LI-COR Biosciences, Lincoln, NE,
USA) at 1/15,000 dilution was used. Image was captured and
analyzed using an Odyssey Clx (LI-COR).
RNA isolation
At sacrifice, the livers were immediately removed and frozen in
liquid nitrogen. RNA from each liver was isolated using Tri-
reagent (Ambion, Austin, TX, USA). DNA contaminants were
removed by TURBO DNAse treatment using the DNA removal
kit from Ambion. RNA was quantified by absorbance at A260/280.
Table 5. Effect of squalene on hepatic gene expression in male wild-type mice.
Gene Control (n = 6) Squalene (n = 7)
Lcat 1.060.2 1.460.7*
Pon1 1.160.5 1.560.4**
Pon2 1.160.5 1.460.6*
Pcyox1 1.060.3 1.260.5
Data (mean 6 SD) represent arbitrary units normalized to the Cyclophilin B, Cyclophilin A and Tbp expressions for control and treated mice according to RT-qPCR.
Statistical analysis was carried out by Mann-Whitney-U test,
*p,0.05,
** p,0.01.
doi:10.1371/journal.pone.0104224.t005
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The integrity of the 28 S and 18 S ribosomal RNAs was verified by
agarose gel electrophoresis.
Quantification of mRNA
The differences in mRNA expression of genes involved in
cholesterol metabolism or antioxidant defense were studied by
quantitative real-time RT-qPCR analysis using equal amounts of
DNA-free RNA from each animal. First-strand cDNA synthesis
was generated using the First Strand Synthesis kit (Thermo
Scientific, Madrid, Spain). Reverse transcriptase-quantitative
polymerase chain reactions (RT-qPCR) were performed using
the Sybr Green PCR Master Mix (Applied Biosystems, Foster
City, CA, USA). The primers were designed using Primer Express
(Applied Biosystems) and checked by BLAST analysis (NCBI) to
verify gene specificity as well as to get amplification of the cDNA
and not of genomic DNA. The sequences were published [67–69].
Real time RT-qPCR reactions were carried out in a Step One
Real Time PCR System (Applied Biosystems) following the
standard procedure. The relative amount of all mRNAs was
calculated using the comparative 22DDCt method and normalized
to the reference Cyclophilin B, Cyclophilin A and TATA box
binding protein, Tbp mRNA expressions [68].
Statistical analysis
Results are expressed as means 6 SD. Unless otherwise stated,
non parametric Mann-Whitney U-test for comparison between
pairs was used for unpaired observations. Association between
variables was assessed by Spearman correlation test. All statistical
tests were performed with the package SPSS version 15.0 (SPSS
Inc, Chicago, IL, USA), and a value of p,0.05 was considered
statistically significant.
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